Format
Sort by

Send to

Choose Destination

Search results

Items: 19

1.

Amyloid negativity in patients with clinically diagnosed Alzheimer disease and MCI.

Landau SM, Horng A, Fero A, Jagust WJ; Alzheimer's Disease Neuroimaging Initiative..

Neurology. 2016 Apr 12;86(15):1377-85. doi: 10.1212/WNL.0000000000002576.

PMID:
26968515
2.

Alzheimer's Disease Assessment Scale-Cognitive subscale variants in mild cognitive impairment and mild Alzheimer's disease: change over time and the effect of enrichment strategies.

Podhorna J, Krahnke T, Shear M, Harrison JE; Alzheimer’s Disease Neuroimaging Initiative..

Alzheimers Res Ther. 2016 Feb 12;8:8. doi: 10.1186/s13195-016-0170-5.

3.

Reference tissue normalization in longitudinal (18)F-florbetapir positron emission tomography of late mild cognitive impairment.

Shokouhi S, Mckay JW, Baker SL, Kang H, Brill AB, Gwirtsman HE, Riddle WR, Claassen DO, Rogers BP; Alzheimer’s Disease Neuroimaging Initiative..

Alzheimers Res Ther. 2016 Jan 15;8:2. doi: 10.1186/s13195-016-0172-3.

4.

A potential endophenotype for Alzheimer's disease: cerebrospinal fluid clusterin.

Deming Y, Xia J, Cai Y, Lord J, Holmans P, Bertelsen S, Holtzman D, Morris JC, Bales K, Pickering EH, Kauwe J, Goate A, Cruchaga C; Alzheimer's Disease Neuroimaging Initiative..

Neurobiol Aging. 2016 Jan;37:208.e1-9. doi: 10.1016/j.neurobiolaging.2015.09.009.

5.

Common Variants in PLD3 and Correlation to Amyloid-Related Phenotypes in Alzheimer's Disease.

Wang C, Tan L, Wang HF, Yu WJ, Liu Y, Jiang T, Tan MS, Hao XK, Zhang DQ, Yu JT; Alzheimer's Disease Neuroimaging Initiative..

J Alzheimers Dis. 2015;46(2):491-5. doi: 10.3233/JAD-150110.

PMID:
26402410
6.

Tau and Amyloid-β Cerebrospinal Fluid Biomarkers have Differential Relationships with Cognition in Mild Cognitive Impairment.

Malpas CB, Saling MM, Velakoulis D, Desmond P, O'Brien TJ; Alzheimer's Disease Neuroimaging Initiative..

J Alzheimers Dis. 2015;47(4):965-75. doi: 10.3233/JAD-142643.

PMID:
26401775
7.

Risk Stratification Using Cerebrospinal Fluid Biomarkers in Patients with Mild Cognitive Impairment: An Exploratory Analysis.

Michaud TL, Kane RL, McCarten JR, Gaugler JE, Nyman JA, Kuntz KM; Alzheimer's Disease Neuroimaging Initiative..

J Alzheimers Dis. 2015;47(3):729-40. doi: 10.3233/JAD-150066.

PMID:
26401707
8.

Cerebral Microbleeds, CSF p-Tau, and Cognitive Decline: Significance of Anatomic Distribution.

Chiang GC, Cruz Hernandez JC, Kantarci K, Jack CR Jr, Weiner MW; Alzheimer's Disease Neuroimaging Initiative..

AJNR Am J Neuroradiol. 2015 Sep;36(9):1635-41. doi: 10.3174/ajnr.A4351.

9.

Nonlinear Association Between Cerebrospinal Fluid and Florbetapir F-18 β-Amyloid Measures Across the Spectrum of Alzheimer Disease.

Toledo JB, Bjerke M, Da X, Landau SM, Foster NL, Jagust W, Jack C Jr, Weiner M, Davatzikos C, Shaw LM, Trojanowski JQ; Alzheimer’s Disease Neuroimaging Initiative Investigators..

JAMA Neurol. 2015 May;72(5):571-81. doi: 10.1001/jamaneurol.2014.4829.

PMID:
25822737
10.

Soluble BACE-1 Activity and sAβPPβ Concentrations in Alzheimer's Disease and Age-Matched Healthy Control Cerebrospinal Fluid from the Alzheimer's Disease Neuroimaging Initiative-1 Baseline Cohort.

Savage MJ, Holder DJ, Wu G, Kaplow J, Siuciak JA, Potter WZ; Foundation for National Institutes of Health (FNIH) Biomarkers Consortium CSF Proteomics Project Team for Alzheimer's Disease Neuroimaging Initiative..

J Alzheimers Dis. 2015;46(2):431-40. doi: 10.3233/JAD-142778.

PMID:
25790831
11.

The mediational effects of FDG hypometabolism on the association between cerebrospinal fluid biomarkers and neurocognitive function.

Dowling NM, Johnson SC, Gleason CE, Jagust WJ; Alzheimer's Disease Neuroimaging Initiative..

Neuroimage. 2015 Jan 15;105:357-68. doi: 10.1016/j.neuroimage.2014.10.050.

12.

Subjective cognitive complaints contribute to misdiagnosis of mild cognitive impairment.

Edmonds EC, Delano-Wood L, Galasko DR, Salmon DP, Bondi MW; Alzheimer’s Disease Neuroimaging Initiative..

J Int Neuropsychol Soc. 2014 Sep;20(8):836-47. doi: 10.1017/S135561771400068X.

13.

Cerebrospinal fluid markers including trefoil factor 3 are associated with neurodegeneration in amyloid-positive individuals.

Paterson RW, Bartlett JW, Blennow K, Fox NC; Alzheimer's Disease Neuroimaging Initiative., Shaw LM, Trojanowski JQ, Zetterberg H, Schott JM.

Transl Psychiatry. 2014 Jul 29;4:e419. doi: 10.1038/tp.2014.58.

14.

Comparing positron emission tomography imaging and cerebrospinal fluid measurements of β-amyloid.

Landau SM, Lu M, Joshi AD, Pontecorvo M, Mintun MA, Trojanowski JQ, Shaw LM, Jagust WJ; Alzheimer's Disease Neuroimaging Initiative..

Ann Neurol. 2013 Dec;74(6):826-36. doi: 10.1002/ana.23908.

15.

Localized hippocampus measures are associated with Alzheimer pathology and cognition independent of total hippocampal volume.

Carmichael O, Xie J, Fletcher E, Singh B, DeCarli C; Alzheimer's Disease Neuroimaging Initiative..

Neurobiol Aging. 2012 Jun;33(6):1124.e31-41. doi: 10.1016/j.neurobiolaging.2011.08.016.

16.

Using CSF biomarkers to replicate genetic associations in Alzheimer's disease.

Schott JM; ADNI Investigators..

Neurobiol Aging. 2012 Jul;33(7):1486.e9-15. doi: 10.1016/j.neurobiolaging.2011.02.008.

17.

Fine mapping of genetic variants in BIN1, CLU, CR1 and PICALM for association with cerebrospinal fluid biomarkers for Alzheimer's disease.

Kauwe JS, Cruchaga C, Karch CM, Sadler B, Lee M, Mayo K, Latu W, Su'a M, Fagan AM, Holtzman DM, Morris JC; Alzheimer's Disease Neuroimaging Initiative., Goate AM.

PLoS One. 2011 Feb 9;6(2):e15918. doi: 10.1371/journal.pone.0015918.

18.

Comparing predictors of conversion and decline in mild cognitive impairment.

Landau SM, Harvey D, Madison CM, Reiman EM, Foster NL, Aisen PS, Petersen RC, Shaw LM, Trojanowski JQ, Jack CR Jr, Weiner MW, Jagust WJ; Alzheimer's Disease Neuroimaging Initiative..

Neurology. 2010 Jul 20;75(3):230-8. doi: 10.1212/WNL.0b013e3181e8e8b8.

19.

Relationships between biomarkers in aging and dementia.

Jagust WJ, Landau SM, Shaw LM, Trojanowski JQ, Koeppe RA, Reiman EM, Foster NL, Petersen RC, Weiner MW, Price JC, Mathis CA; Alzheimer's Disease Neuroimaging Initiative..

Neurology. 2009 Oct 13;73(15):1193-9. doi: 10.1212/WNL.0b013e3181bc010c.

Items per page

Supplemental Content

Loading ...
Support Center